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275* Infection by Nocardia farcinica in CF
J. Beucher1, C. Belleguic1, G. Brinchault1, E. Deneuville1, P.Y. Donnio1,
M. Roussey1. 1CF Centre University Hospital, Rennes, France
Infection by Nocardia is an uncommon disease, affecting immunocompromised
patient. This bacteria has rarely been isolated from CF patients, especially without
any oral corticosteroids. We report a case of a patient with CF harbouring Nocardia
farcicana.
Methods: the patient is a 18-year-old male with diagnosis of CF at 8 years
old (F508del/G85E). An allergic bronchopulmonary aspergillosis was treated in
1998 with itraconazole and a primocolonization with Pseudomonas aeruginosa
(Pa) was eradicated in 2003. From may 2006, he presented recurrent left and
right pneumothorax. In june 2006, he presented with dyspnea, fever and nodular
eruption on the ankles. Chest X-Ray and CT scan revealed a right pneumothorax,
severe bronchiectasis and bilateral alveolar consolidation. Sputum specimen isolated
Nocardia forcicana, without any other pathogens. A treatment with intravenous
cotrimoxazole associated with imipenem and amikacin during 3 weeks was initiated
followed by oral cotrimoxazole during 9 months. The symptoms and the alveolar
consolidation CT scan improved.
During 2007, his respiratory condition worsened. His FEV1 declined from 50 to
26% predicted, pneumothorax recurred. He was presenting a chronic colonization
with Pa and was expecting a lung transplantation. Unfortunately he died in 2008.
Results: Nocardia, a gram positive bacilli can cause mainly pulmonary infection,
usually in the setting of immunodepression. The most frequent is Nocardia aster-
oides. In CF, very few cases have been reported, almost always Nocardia asteroides,
but exceptionnaly Nocardia forcicana.
Conclusion: In case of worsening pulmonary condition in CF patients, physicians
managing CF patients should consider such uncommon organisms in patients failing
to respond to usual therapy or worsen their lung’s function without any explanation.
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Case report: The 11 year old CF patient suffered from chronic rhinosinusitis as
predominant symptom. He was included in our longitudinal study on non-invasive
assessment of upper and lower-airway colonisation with P. aeruginosa (P.a.).
In June 2006 P.a. was detected in his airways for the ﬁrst time: exclusively in nasal
lavage. Despite a two-weeks anti-pseudomonas i.v.-course the bacterium again was
detected in upper airway sampling in August 2006, but again not in lower airway
probes.
In off-label use the patient inhaled Tobramycin 80mg (Gernebcin™) once daily
for 4 weeks with the novel Pari Sinus™ nebuliser, which in in-vitro analyses was
shown to deposit aerosol into the paranasal sinuses. Since then, he did not reveal
positive P.a. samples from upper and lower airways in continuous monitoring and
P.a. antibodies in serum remained negative.
Discussion: The upper airways are regularly involved in CF as the epithelial
CFTR-defect equally concerns sinonasal mucosa. Impaired clearance of this airway
segment implies the risk of ﬁrst colonisation with P.a. and its persistence. This
would not have been detected in our patient applying the current best standards of
CF-care.
Secondary, our case report includes the ﬁrst record on antibiotic inhalation with
the novel Pari Sinus™ device. After sinonasal therapy with Tobramycin we did not
detect P.a. in the patients airways in frequent controls.
Conclusion: Upper airway sampling with non-invasive methods like nasal lavage
can allow earlier detection of P.a.-colonisation. Eradication of P.a. in this airway
segment could have the potential to postpone chronic pulmonary P.a.-infection, the
leading cause of morbidity and mortality in CF.
277* Lung transplantation in patients with cystic ﬁbrosis and
Mycobacterium abscessus infection
M. Gilljam1, M. Silverborn2, H. Schersten2. 1Dept Respiratory Medicine
and Allergology, Sahlgrenska University Hospital, Go¨teborg, Sweden; 2Dept
Cardiothoracic Surgery, Sahlgrenska University Hospital, Go¨teborg, Sweden
Mycobacterium abscessus is a multiresistent rapid-growing non-tuberculous my-
cobacteria. M. abcessus lung infection is difﬁcult to treat and has become an
increasing problem in patients with cystic ﬁbrosis (CF). Fatal infection has been
described after lung transplantation and M. abscessus infection has thus been
considered a relative contraindication for transplantation.
We have performed double lung transplantation in three CF patients with ongoing
treatment for chronic M. abscessus lung infection and, most recently, one CF patient
with intermittent growth. The surgical approach was sternotomy (2), clamshell (1)
and bilateral single sequential lung transplantation through anterior thoracotomy (1).
The patients were 10, 28, 26 and 20 years old, respectively, at the time for surgery
and all are alive and have a stable lung function after 6.5, 4, 2.5 and 0.8 years.
Despite prolonged post-operative treatment with a combination of antimycobacterial
drugs, the ﬁrst three patients developed severe mycobacterial skin infection with
abscesses, requiring skin transplantation in two cases. They were also treated for
infections with Pseudomonas aeruginosa (3) and Aspergillus fumigatus (1). All
three have developed severe kidney dysfunction and hearing impairment due to
prolonged aminoglycoside treatment.
Conclusion: Lung transplantation in patients with M. abscessus lung infection is
feasible but associated with severe complications.
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Early recognition and treatment of lobar and segmental atelectasis is essential
in order to prevent progression of bronchiectasis and irreversible collapse. A
common cause of atelectasis in patients with cystic ﬁbrosis (CF) is mucus plugging
and secretions secondary to allergic bronchopulmonary aspergillosis (ABPA) and
aspergillus bronchitis. Despite early reservations it is now accepted that bronchial
lavage and instillation of rhDNase is effective in re-expanding collapsed lobes. In a
previous case series; however, a signiﬁcant number of patients failed to re-expand
lung despite this approach in conjunction with standard medical management.
We report a series of 5 CF patients (2 males, 3 females, ages 7−66 years) who
presented with pulmonary exacerbations and evidence of lobar collapse radiolog-
ically between 2007 and 2008. All patients were diagnosed with either ABPA or
aspergillus bronchitis and treated with steroids, anti-fungal medication, nebulised
rhDNAse, and physiotherapy. Patients underwent sequential ﬂexible bronchoscopy
for lavage and instillation of rhDNase; procedures were performed at least one week
apart (see Table 1). All patients achieved complete resolution and lung function
returned to baseline.
In conclusion, sequential bronchoscopy is capable of achieving complete radiolog-
ical resolution in patients who have failed to re-expand after a single procedure.
Table 1. Outcome of sequential bronchoscopies
Patient Gender/
age (years)
Microbiology Site of atelectasis Instilled dose
rhDNase
Number of
bronchoscopies
Complete
resolution
1 M/17 P. aeruginosa/
A. fumigatus
Left upper lobe 5mg 2 Yes
2 F/17 A. fumigatus Right upper lobe 5mg 2 Yes
3 M/66 P. aeruginosa/
A. fumigatus
Right lower lobe 5mg 4 Yes
4 F/7 A. fumigatus Left upper lobe 2.5mg 3 Yesa
5 F/8 A. fumigatus Right lower lobe 2.5mg 2 Yesb
aAfter 2 weeks; bAfter 8 weeks.
